Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neurofilament light polypeptide (NF-L, sometimes called NF68 or NEFL) is a neuron-specific intermediate filament protein and a key component of the neuronal cytoskeleton. It forms the core of neurofilament heteropolymers with other subunits (NF-M, NF-H, α-internexin, or peripherin), providing structural support for axons and contributing to the maintenance of axonal diameter and nerve conduction velocity[2][4][5][10]. NF-L is the most abundant subunit of neurofilaments and is especially concentrated in large axons. Elevated levels of NF-L are released into CSF and blood after axonal injury or neurodegeneration, making it an important biomarker for monitoring disease activity and prognosis in various neurological disorders[8]. NF-L does not serve as a classical pharmacological drug target, but its measurement is clinically valuable for assessing neuroaxonal loss.
Not applicable; not currently a direct therapeutic target
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neurofilament light polypeptide (NF-L (or NFL)).